How to Get Jatenzo in Indiana: Prescription, Telehealth, and Pharmacy Guide

What Is Jatenzo and Why Does It Matter for Indiana Patients

Jatenzo is the only FDA-approved oral testosterone undecanoate formulation in the United States. The FDA granted approval in March 2019 under NDA 022504 based on the LIBERTY trial data submitted by Clarus Therapeutics (now licensed to Tolmar). 1 Unlike older methyltestosterone oral products, testosterone undecanoate absorbs via intestinal lymphatics rather than first-pass hepatic metabolism, which avoids the hepatotoxicity risk associated with 17-alpha alkylated androgens. 2

Each soft-gel capsule contains 237 mg of testosterone undecanoate, delivering roughly 158 mg of testosterone base. The starting dose is 237 mg twice daily with a meal containing at least 20 grams of fat. At the 6-week titration visit, the prescriber measures a serum testosterone 3 to 5 hours after the morning dose and adjusts to 158 mg twice daily if levels exceed 1 to 050 ng/dL, or increases to 396 mg twice daily if levels remain below 400 ng/dL. 3

Swerdloff et al. (J Clin Endocrinol Metab, 2020) reported that 87% of men treated with oral testosterone undecanoate achieved an average testosterone concentration (Cavg) within the normal physiologic range of 300 to 1 to 050 ng/dL over a 52-week study period (N=166 completers). 4 Mean Cavg was 558 ng/dL at the titrated dose. That trial also showed a mean 3.9 mmHg increase in systolic blood pressure, a cardiovascular signal that prescribers in Indiana must document and monitor. 4

Blood pressure elevation carries a black-box warning on the Jatenzo label. The FDA requires prescribers to check blood pressure before initiating therapy and at every follow-up visit, with instructions to reduce dose or discontinue if hypertension becomes uncontrolled. 3 Indiana clinicians ordering Jatenzo through telehealth must be able to review home blood pressure logs or recent vital signs before issuing each refill.

Who Qualifies for a Jatenzo Prescription in Indiana

Jatenzo is FDA-approved for adult males with primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired). 3 Indiana prescribers follow the Endocrine Society's 2018 clinical practice guideline, which recommends confirming diagnosis with two separate fasting morning testosterone measurements on different days, both below 300 ng/dL, accompanied by consistent signs and symptoms. 5

The Endocrine Society guideline states: "We recommend confirming the diagnosis by measuring testosterone levels on two separate occasions because of the variability of testosterone levels and the significant placebo effect noted in trials." 5 That two-sample requirement is not negotiable under most Indiana commercial insurance plans either; prior authorization forms from Anthem Blue Cross Blue Shield Indiana and Humana Indiana both list it as a hard criterion.

Symptoms that support the diagnosis include decreased libido, erectile dysfunction, fatigue, depressed mood, reduced lean mass, and decreased morning erections. The American Urological Association's 2018 guideline on testosterone deficiency syndrome lists these under the clinical syndrome definition and ties them to total testosterone thresholds. 6 A symptom checklist score alone, without confirmed biochemical deficiency, is not sufficient grounds for prescribing under Indiana's standard of care.

Men with prostate cancer, breast cancer, untreated severe obstructive sleep apnea, or hematocrit above 54% are contraindicated per the FDA label. 3 Indiana providers must document that none of these exclusions are present before generating a prescription.

Required Labs Before Starting Jatenzo in Indiana

The following lab panel represents the minimum pre-prescribing workup aligned with Endocrine Society (2018) 5 and AUA (2018) 6 guidelines, organized here as a structured ordering framework specific to Jatenzo's black-box blood pressure and hematocrit risks:

Diagnostic Confirmation Labs (draw 1, fasting, 7 to 10 a.m.)

• Total serum testosterone (LC-MS/MS preferred for accuracy below 300 ng/dL)
• Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to classify primary vs. hypogonadotropic origin
• Sex hormone-binding globulin (SHBG) if borderline total testosterone

Diagnostic Confirmation Labs (draw 2, separate day, same conditions)

• Total serum testosterone (repeat)

Safety and Baseline Labs (at enrollment)

• Complete blood count with hematocrit (contraindicated if hematocrit above 54%) 3
• PSA (prostate-specific antigen) for men 40 years and older, or 35 and older with family history of prostate cancer 6
• Blood pressure (in-office or validated home monitor)
• Comprehensive metabolic panel (liver function, renal function)
• Lipid panel (testosterone therapy may reduce HDL) 7
• Estradiol (LC-MS/MS) if gynecomastia is present at baseline

Monitoring Labs (6-week titration visit)

• Serum testosterone drawn 3 to 5 hours after the morning Jatenzo dose
• Hematocrit
• Blood pressure

Monitoring Labs (3 months, then annually)

• Total testosterone, hematocrit, PSA, blood pressure, lipid panel

Indiana telehealth providers typically accept recent lab results (drawn within 90 days) from any CLIA-certified laboratory, including Quest Diagnostics and LabCorp, both of which have patient service centers throughout Indianapolis, Fort Wayne, Evansville, and South Bend.

How Telehealth Prescribing Works for Jatenzo in Indiana

Indiana permits telehealth prescribing of controlled substances under state law provided the prescriber holds an active Indiana DEA registration and has conducted a valid patient evaluation. 8 Testosterone is a Schedule III controlled substance under federal law, and the DEA's Ryan Haight Online Pharmacy Consumer Protection Act requires at least one in-person evaluation before a provider may prescribe a Schedule III drug via telemedicine. 9 The DEA proposed telemedicine rules in 2023 would extend some exceptions, but as of early 2025, the in-person evaluation requirement generally still applies for initiating testosterone prescriptions via telehealth unless the provider falls under a specific DEA telemedicine registration exception.

In practice, this means most Indiana telehealth TRT platforms either (a) arrange an in-person affiliate visit for the initial evaluation, (b) accept a recent in-person evaluation by another licensed Indiana provider, or (c) operate under an existing patient-provider relationship. Once the in-person component is satisfied, all subsequent follow-up visits, lab reviews, and refills may proceed via synchronous video or asynchronous messaging, consistent with Indiana's Telehealth Advisory Opinion from the Indiana Medical Licensing Board. 8

The typical telehealth workflow in Indiana runs as follows. The patient completes an online intake form, uploads lab results, and schedules a synchronous video visit. The provider reviews the two qualifying testosterone values, screens for contraindications, documents blood pressure and hematocrit, obtains informed consent for the black-box blood pressure warning, and then transmits a controlled-substance prescription electronically to a pharmacy licensed in Indiana. Most telehealth platforms partnered with specialty pharmacies can have the first supply shipped within 3 to 7 business days after the prescribing visit.

Indiana does not impose a state-level prior authorization for telehealth-initiated testosterone prescriptions, but each commercial insurer applies its own prior authorization policy regardless of prescribing channel.

Navigating Prior Authorization for Jatenzo in Indiana

Jatenzo carries a high wholesale acquisition cost, approximately $540 to $620 per 30-day supply as of 2025. Most Indiana commercial plans (Anthem Blue Cross Blue Shield, Cigna, Aetna, UnitedHealthcare) place it on a non-preferred specialty tier requiring prior authorization. Indiana Medicaid covers Jatenzo only for the Type 2 diabetes indication; male hypogonadism is excluded from the Medicaid preferred drug list in Indiana.

Prior authorization documentation typically requires:

1. Two qualifying testosterone lab values (both below 300 ng/dL on separate mornings)
2. ICD-10 diagnosis code: E29.1 (testicular hypofunction), E23.0 (hypopituitarism), or Q98.0/Q98.1 for Klinefelter syndrome
3. Documentation of hypogonadism symptoms and their duration
4. Prescriber attestation that alternative testosterone formulations (gel, injection, patch) were tried and failed, or are contraindicated or declined by the patient
5. Baseline PSA value for men over 40
6. Blood pressure documentation and acknowledgment of the black-box warning

Step therapy requirements vary by insurer. Anthem Indiana often requires a 90-day trial of a topical testosterone gel (AndroGel 1.62%, Testim, or generic) before approving Jatenzo. UnitedHealthcare Indiana may accept documented patient preference for an oral formulation if the prescriber provides a clinical rationale. Resubmission after a soft denial typically succeeds when the prescriber adds a letter of medical necessity specifying absorption variability with transdermal products or skin contact transfer risk in households with children or women of childbearing potential.

The Tolmar patient assistance program, Jatenzo Access, offers a $0 co-pay card for commercially insured patients who are approved, bringing out-of-pocket cost to $0 for eligible patients for up to 12 months. Patients without commercial insurance may apply for the Tolmar patient assistance program for income-based free product.

Pharmacy Options in Indiana for Jatenzo

Jatenzo is a brand-name drug with no FDA-approved generic as of early 2025. Retail pharmacy options in Indiana include major chains (CVS, Walgreens, Walmart Pharmacy, Kroger Pharmacy) and independent pharmacies. Because Jatenzo requires refrigeration upon receipt and has specific dispensing instructions tied to the REMS-adjacent counseling requirements on the label, patients should confirm that their chosen pharmacy carries it in stock or can order it within 1 to 2 business days from a pharmaceutical distributor. 3

For patients who cannot access brand Jatenzo at an affordable cost, 503A compounding pharmacies licensed in Indiana may prepare oral testosterone undecanoate capsules. The FDA does not recognize 503A compounds as equivalent to the approved drug; they are prepared on a patient-specific, prescription basis without FDA pre-market review. The Pharmacy Compounding Accreditation Board (PCAB) accreditation is a reasonable quality indicator when selecting a 503A pharmacy. Compounded oral testosterone undecanoate products have not undergone the pharmacokinetic validation that the Swerdloff et al. trial applied to the branded formulation. 4

Mail-order pharmacies with Indiana dispensing licenses may also ship Jatenzo to Indiana addresses. Schedule III prescriptions transmitted electronically from a licensed Indiana provider to a licensed out-of-state mail-order pharmacy are lawful under the DEA's electronic prescribing of controlled substances (EPCS) regulations, provided the pharmacy holds a DEA registration and the respective state pharmacy board licenses it to deliver into Indiana. 9

Who Can Prescribe Jatenzo in Indiana

Any licensed prescriber with an active Indiana DEA Schedule III registration may write a Jatenzo prescription. That includes MDs and DOs with full licensure, nurse practitioners (NPs) operating under a collaborative practice agreement with a supervising physician (Indiana is not a full-practice-authority state for NPs as of 2025), and physician assistants (PAs) practicing under supervision. 8

Specialists who commonly prescribe Jatenzo in Indiana include endocrinologists, urologists, and men's health-focused internal medicine physicians. Primary care physicians increasingly prescribe TRT as well, particularly through telehealth platforms that provide protocol support and lab review tools. Prescribers unfamiliar with the blood pressure black-box warning or the titration schedule should review the full Jatenzo prescribing information before initiating therapy. 3

The Endocrine Society's 2018 guideline notes: "We suggest that clinicians consider testosterone therapy for men with age-related decline in testosterone only when there is clear biochemical evidence of testosterone deficiency and the patient has significant symptoms that are likely to respond to treatment." 5 That framing shapes how Indiana prescribers document the clinical necessity required for prior authorization and licensing-board accountability.

Transferring an Existing Jatenzo Prescription to Indiana

Patients relocating to Indiana with an active Jatenzo prescription from another state may transfer it under the following conditions. Schedule III controlled substance prescriptions may be transferred between pharmacies once, under DEA regulations, if both pharmacies are registered DEA entities. 9 Electronic prescriptions for Schedule III drugs cannot be transferred at all after the original transmission to a pharmacy; the patient must obtain a new prescription from an Indiana-licensed prescriber.

The most practical path for patients moving to Indiana is to schedule a telehealth visit with an Indiana-licensed provider, share prior records (diagnosis documentation, labs, previous prescriber notes), and have a new prescription issued. Because the two qualifying testosterone values from a prior state are still valid if drawn within the same episode of care and the patient remains symptomatic, many providers will accept them without repeating the full baseline panel immediately, though a new blood pressure check and PSA review are standard before issuing the first Indiana prescription.

Patients maintaining care with an out-of-state telehealth provider after moving to Indiana should verify that the provider holds an active Indiana medical or nursing license and Indiana DEA registration. Prescribing to an Indiana address without Indiana licensure violates state law and the DEA registration requirement.

Blood Pressure Monitoring: Indiana-Specific Practical Considerations

The Jatenzo black-box warning on blood pressure is the most operationally significant safety requirement for Indiana telehealth prescribers. The FDA label states that increases in blood pressure associated with testosterone therapy may increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. 3 The 3.9 mmHg mean systolic increase observed in the Swerdloff et al. 52-week trial 4 translates to a clinically meaningful population-level cardiovascular risk when extrapolated across large cohorts, though absolute individual risk varies by baseline cardiovascular status.

The American Heart Association defines stage 1 hypertension as systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg. 10 Indiana telehealth platforms prescribing Jatenzo should establish a written protocol specifying what blood pressure threshold triggers dose reduction vs. antihypertensive initiation vs. Jatenzo discontinuation. Patients should own a validated home blood pressure cuff (validated by the British and Irish Hypertension Society list or the American Medical Association's validated device list) and log readings at least twice weekly during the first 3 months of therapy.

Patients with pre-existing stage 2 hypertension (systolic at or above 160 mmHg) should not initiate Jatenzo until blood pressure is controlled, consistent with the FDA label's contraindication language. 3

Hematocrit Monitoring and Dose Adjustment in Indiana Patients

Testosterone therapy stimulates erythropoiesis. The Endocrine Society guideline recommends checking hematocrit at 3 months and 12 months in the first year of treatment, then annually. 5 If hematocrit exceeds 54%, the prescriber should withhold Jatenzo until hematocrit normalizes, then restart at a lower dose or discontinue permanently if elevation recurs. 3

Men at elevated baseline hematocrit risk include those with obstructive sleep apnea, polycythemia vera, heavy smokers, and men living at high altitude. Indiana's highest elevations are modest (under 1,300 feet), so altitude is rarely a compounding factor, but sleep apnea screening is warranted given that the CDC estimates 1 in 4 Indiana adults is obese and obesity is the primary risk factor for OSA. 11 Untreated severe OSA is a contraindication to Jatenzo under the FDA label. 3

Patients with hematocrit between 50% and 54% at baseline should be started at the lowest effective dose (158 mg twice daily after a downward titration at 6 weeks) and monitored at 6-week intervals until stability is confirmed.

Cardiovascular Evidence and the TRAVERSE Trial Context

The TRAVERSE trial (N=5,246, mean age 65.6 years, all with pre-existing cardiovascular disease or high cardiovascular risk) evaluated testosterone replacement in men with hypogonadism and found non-inferiority to placebo on the primary MACE endpoint (hazard ratio 1.02 to 95% CI 0.86 to 1.21) at a median follow-up of 22 months. 12 That trial used topical testosterone gel, not oral testosterone undecanoate, so the blood pressure findings from the Jatenzo-specific data remain the more relevant safety reference for this formulation. 4

The FDA cited TRAVERSE in its 2023 label communications, noting that while the MACE non-inferiority signal is reassuring for the class, prescribers should still counsel patients on cardiovascular risk and monitor blood pressure specifically for Jatenzo given its formulation-specific pharmacokinetic profile. Patients with prior MI, stroke, or heart failure within 6 months should not start Jatenzo until their cardiovascular condition is stable and a cardiologist has reviewed the risk-benefit balance.

Costs and Patient Assistance for Indiana Residents

Without insurance, Jatenzo's retail price ranges from approximately $540 to $620 per month for 60 capsules (30-day supply at twice-daily dosing). Indiana GoodRx or similar discount programs do not apply to Jatenzo because it does not have a generic. 13

Tolmar's co-pay assistance card brings out-of-pocket cost to $0 per month for commercially insured patients who meet eligibility criteria. Patients should visit Tolmar's official program page or call the Jatenzo Access support line to enroll. Eligibility typically excludes patients covered by federal programs (Medicare, Medicaid, TRICARE, Veterans Affairs). Indiana Medicaid, as noted, does not cover Jatenzo for male hypogonadism regardless of prior authorization. 14

For uninsured or underinsured Indiana patients who do not qualify for the co-pay card, the Tolmar patient assistance program may provide free medication based on income. Applications generally require proof of income (tax return or pay stubs), proof of residency, and the prescriber's NPI number.